Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040069 | 0.86 | KDM4E (0.43) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL2796862 | 0.80 | ALDH1A1 (0.47) | KMT2AKDM4EALDH1A1TDP1HSD17B10 | |
| SCHEMBL2797333 | 0.78 | UBE2M (0.38) | KMT2AKDM4EALDH1A1HPGDMAPK1 | |
| SCHEMBL2798210 | 0.76 | LMNA (0.41) | KMT2AALDH1A1HTTMAPTLMNA | |
| SCHEMBL2797796 | 0.73 | LMNA (0.50) | KMT2AALDH1A1HSD17B10HTTMAPK1 | |
| SCHEMBL2797859 | 0.72 | HTT (0.45) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL2796755 | 0.72 | HTT (0.44) | KMT2AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2796082 | 0.70 | KCNH2 (0.39) | — | |
| SCHEMBL5046803 | 0.69 | KCNH2 (0.49) | KMT2AALDH1A1HPGDHTTMAPT | |
| SCHEMBL2796259 | 0.69 | KCNH2 (0.39) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | KMT2A 1173/4885KDM4E 2360/4885ALDH1A1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.